Background Sorafenib, a drug that inhibits Raf serine/ threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma. Aims To explore the efficacy and safety of sorafenib for treating advanced HCC, and to identify clinical factors that might affect that efficacy and safety. Methods We conducted a systematic review using the PRISMA guidelines to identify prospective studies on sorafenib used alone or in combination with systemic and/ or loco regional anti-tumor therapy for treating advanced HCC. Results We identified 21 prospective trials of sorafenib treatment alone (7) or combined with other treatment (14). In randomized, placebo-controlled trials, sorafenib prolonged overall survival by 2.3-2.8 months, extended the time to tumor progression by 1.4-2.7 months, and increased disease control by 11-19 %. OS and DCRs were lowest for studies with the highest percentage of hepatitis B patients. Most studies reported major side effects (diarrhea, fatigue, and hand-foot syndrome) in \15 % of patients, with greater incidence in patients with advanced cirrhosis and those treated with sorafenib in combination with 5-FU drugs. Conclusions Treatment with sorafenib results in statistically significant, but clinically modest, improvements in OS, TTP, and DCR. For patients with hepatitis B, response seems to be poorer than for those with hepatitis C. The frequency of hand-foot syndrome seems to be higher when sorafenib is used in advanced cirrhosis and is combined with 5-FU drugs. It is not clear that sorafenib combined with other treatments is more effective than sorafenib alone.
Background
Worldwide, liver cancer is the sixth most common malignancy and the third most common cause of cancer-related deaths [1] . Hepatocellular carcinoma (HCC) accounts for 85-90 % of all primary hepatic malignancies [2, 3] . Cirrhosis is a major risk factor for HCC, and 60-80 % of these tumors arise in patients with cirrhosis. The major chronic liver diseases underlying the development of cirrhosis and HCC include chronic viral hepatitis (B and C), non-alcoholic steatohepatitis, and alcoholic liver disease. In the United States, the incidence of HCC has increased from 1.4 cases/100,000 in 1976-1980 to approximately five cases/ 100,000 in 2003-2006 [4] [5] [6] . A major reason for this increasing incidence of HCC in Americans is the increased frequency of hepatitis C infection acquired in the 1960s and 1970s because of intravenous drug use, sexual contacts, and blood transfusion in the era before the availability of serologic tests for hepatitis C [7] .
HCC develops in a stepwise process that involves activation of oncogenes and inactivation of tumor suppressor genes through genetic and epigenetic alterations that develop in patients with chronic hepatitis and cirrhosis.
Alterations that cause over-activation of the Raf/MEK/ ERK mitogen-activated protein (MAP) kinase signaling pathway seem to be particularly important in the development of HCC [8] [9] [10] . The MAP kinases are serine/ threonine protein kinases that normally regulate important cellular activity, for example proliferation and apoptosis. Abnormalities in cellular proliferation and apoptosis are important physiological indicators of malignancy.
The Raf/MEK/ERK pathway can be over-activated through a variety of mechanisms including oncogenic mutations in the upstream Ras gene [11] ; over-expression of growth factors (e.g. platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF)) and their receptor tyrosine kinases that induce Raf activation; stimulation by hepatitis B virus protein 9 (HBx) and PreS2-activator large surface protein; and stimulation by hepatitis C virus core proteins via signaling intermediates [12] [13] [14] . When the Raf/MEK/ERK pathway is activated, it can increase cell proliferation and survival directly, and can indirectly stimulate angiogenesis by increasing the production of VEGF and PDGF [15] (Fig. 1 ). These processes are required for tumor growth and, thus, the molecular components of the Raf/MEK/ERK signaling pathway are potential therapeutic targets for HCC [16] .
Sorafenib is a biaryl urea that blocks the Raf/MEK/ERK pathway by inhibiting Raf serine/threonine kinase isoforms (e.g. Raf-1 and B-Raf). Sorafenib also inhibits the upstream receptor tyrosine kinases that are important in angiogenesis, including VEGFR-2, VEGFR-3, PDGFR-beta, and kit. Thus, sorafenib can induce tumor cell death and inhibit angiogenesis. Sorafenib has also been shown to induce apoptosis in several tumor cell lines through mechanisms that are not well established [16, 17] . Proposed mechanisms include inhibition of phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), which (when phosphorylated) mediates the up-regulation of some oncogenic proteins, and the downregulation of myeloid cell leukemia-1 (Mcl-1), an anti-apoptotic protein. Both inhibition of eIF4E phosphorylation and loss of Mcl-1 have been documented in association with sorafenib-induced apoptosis, irrespective of the drug's effects on the MEK/ ERK pathway [18] . The pro-apoptotic activity of sorafenib can be enhanced significantly by addition of some chemotherapeutic agents (e.g. gemcitabine) and by agents that inhibit signal transduction pathways (e.g. sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR) pathway) [19, 20] . These observations suggest that the combination of sorafenib with chemotherapeutic agents or signal transduction inhibitors might have better anti-tumor activity than any of these agents given alone [21] . Sorafenib is the first FDA-approved systemic therapy for patients with advanced HCC not amenable to treatment by surgical resection or liver transplantation. In clinical practice, sorafenib is not usually given until such patients have failed to respond to locoregional therapy, for example transcatheter arterial chemoembolization (TACE). Prospective clinical trials have assessed the anti-HCC effects of sorafenib alone, sorafenib with systemic chemotherapy, and sorafenib with locoregional therapy. We have conducted a systematic review of these studies to answer five questions: 1. What is the efficacy of sorafenib in treating advanced HCC using overall survival, time to tumor progression, and disease control rate as criteria for evaluation? 2. What is the safety of sorafenib treatment, using the incidence of major (grade 3 or 4) side effects as the evaluation criterion? 3. Does the efficacy of sorafenib treatment vary depending on gender, age, stage of cirrhosis, and etiology of the underlying liver disease (especially hepatitis B and C)? 4. Which types of sorafenib combined therapy has been assessed in prospective clinical trials? 5. Are there advantages of sorafenib combined treatment over sorafenib alone?
Materials and Methods

Search Strategy
We followed the PRISMA recommendations for systematic literature analysis [22] . We performed computer-based searches of the PubMed database [23] and the ISI web of science database [24] for clinical trials in original articles or conference abstracts between January 2000 and November 2011. We searched using combinations of the terms: ''sorafenib'' or ''nexavor'' and ''hepatocellular carcinoma'' or ''HCC'' in the title or abstract fields. Clinical trials published in English were identified. We screened each abstract resulting from these searches for eligibility. We also examined reference lists of each selected original article or conference abstract and the protocol registration system of clinical trials [25] to identify additional articles that might meet our eligibility requirements. Any discrepancies among reviewers were resolved by consensus discussion.
Selection of Clinical Trials
Article selection was determined a priori by use of three inclusion criteria: 1. only adults were included in the clinical trial; 2. only patients with advanced HCC were included; and 3. the study used sorafenib alone or sorafenib-based therapy combined with one or more other treatments (systemic or locoregional therapy).
We excluded: 1. review articles; 2. editorials; 3. letters to the editor; 4. retrospective studies; 5. research protocols; 6. duplicated records; 7. sub-analyses of the same clinical trial; 8. preliminary results if the final study results had been published; 9. interim reports if the final results had been published; and 10. studies including patients with other malignancies besides HCC.
Data Abstraction
For clinical trials with sorafenib treatment alone, the data extracted from each report were: publication type (original article or conference abstract), phase of the clinical trial, number of patients, percentage of men; median age of study participants, percentage of patients with Child-Pugh score A, B, or C, percentage of patients with hepatitis B or hepatitis C; overall survival (OS), time to tumor progression (TTP), disease control rate (DCR), and frequency of the three major adverse effects of sorafenib (hand-foot syndrome, diarrhea, and fatigue). Information extracted for clinical trials of sorafenib combined with other treatment included all of the information extracted for the trials with sorafenib alone plus information on the combined treatment regimen.
Results
Systematic Review Flow
The flow chart of the systematic review is shown in Fig. 2 . Our initial search yielded 133 articles including 14 from PubMed and 119 from ISI Web of Science, clinical trial registry and relevant references. Ultimately, 21 prospective clinical trials were chosen for review including seven of sorafenib treatment alone and 14 of sorafenib plus other treatments; sorafenib was combined with systemic chemotherapy in nine trials and with locoregional therapy in the other five trials.
Studies on Treatment with Sorafenib Alone
Results from the seven trials of sorafenib alone, which included a total of 1,072 patients, are summarized in Table 1 . Two reports described phase 3 randomized, placebo-controlled clinical trials [26, 27] , three described phase 2 trials [28] [29] [30] , and two described phase 1 trials [31, 32] . The percentage of male patients ranged from 71 [28] to 100 % [32] . Median age ranged from 51 [27] to 72 years [29] . Among the five trials providing precise OS and TTP data [26-28, 30, 31] [26, 27] studies were the two highest quality reports (phase 3 randomized, placebocontrolled trials). Almost all patients in both studies had Child A cirrhosis (95 and 97 %), but the frequency of hepatitis B infection was much lower in the Asian-Pacific trial (71 vs. 19 %). For the sorafenib and placebo groups in the SHARP trial, the OS was 10.7 versus 7.9 months (P \ 0.05) and the TTP was 5.5 versus 2.8 months (P \ 0.05), respectively [26] . For the sorafenib and placebo groups in the Asian-Pacific trial, the OS was 6.5 versus 4.2 months and the TTP was 2.8 versus 1.4 months, respectively [27] . Among the six studies that provided data on Child-Pugh scores [26] [27] [28] [30] [31] [32] , most patients had Child A cirrhosis. The frequency of Child B patients ranged from 3 [27] to 52 % [31] , and only one study included any patients (two) with Child C cirrhosis [30] . It seems that the development of HFS may be more frequent in patients with Child B cirrhosis. For example, the study with highest percentage of Child B patients (52 %) also had the highest the incidence of HFS (27 %) [31] among these seven trials. However, the large phase II trial by Abou-Alfa et al. [28] in which 28 % of the total study population of 137 patients had Child B cirrhosis, had a relatively low frequency of HFS (5 %).
It seems that hepatitis B infection might adversely affect the response to sorafenib. The studies with the highest percentages of patients with hepatitis B also had the lowest OS and DCRs. For example, the Hongkong trial [30] , which had the highest percentage of hepatitis B patients (90 %), reported the lowest OS (5 months) and DCR (26 %). In contrast, the Japanese trial, in which 74 % of patients had hepatitis C, had the longest OS (15.6 months) and the highest DCR (82 %) [31] .
Among seven studies on sorafenib alone that provided data on OS, 3 (43 %) described an OS that was clearly [10 months. Among six studies on sorafenib alone that provided data on TTP, none reported a TTP [6 months. Among seven studies on sorafenib alone that provided data on DCR, three (43 %) reported a DCR [60 %.
In summary, the seven studies summarized in Table 1 show that sorafenib treatment alone results in statistically significant but clinically modest, improvements in OS, TTP, and DCR in patient populations comprising primarily men under age 70 who have advanced HCC with Child A cirrhosis. Very few data are available on the effects of sorafenib for women, for patients older than 70, and for patients with advanced cirrhosis. Patients with hepatitis B seem to have a poorer response to sorafenib treatment alone than patients with hepatitis C, and side effects of sorafenib are frequent, especially for patients with advanced cirrhosis.
Studies on Sorafenib Combined with Other Treatments
Results from the 14 studies on sorafenib combined with other treatment, which included a total of 470 patients, are summarized in Table 2 . Ten studies were phase 2 trials [33] [34] [35] [36] [37] [38] [39] [40] [41] 46] , three were phase 1 trials [41] [42] [43] , and one was a phase 1/2 trial [44] . Nine studies used sorafenib combined with other systemic therapy [33-39, 42, 43] , and five used sorafenib combined with locoregional therapy [39, 40, [43] [44] [45] . Most of the reports are relatively small case series describing preliminary results, and complete data on patient populations and outcomes often are not provided. Nevertheless, the patient populations seem similar to those in trials of sorafenib alone, comprising predominantly men under age 70 who have advanced HCC with Child A cirrhosis. OS ranged from 7.4 [37] to 13.7 months [36] , TTP ranged from 3.7 [37] to 7.6 months [34] , and DCRs ranged from 48 [34] to 100 % [40] . There was only one randomized, controlled trial [36] in which patients received doxorubicin plus sorafenib or doxorubicin plus placebo. Compared with the 49 patients who received doxorubicin plus placebo, the 47 patients treated with doxorubicin and sorafenib had significantly better OS (13.7 vs. 6.5 months), TTP (6.4 vs. 2.8 months) and DCR (62 vs. 29 %). The frequency of side effects described in these studies is generally similar to that for patients treated with sorafenib alone. However, the frequency of hand-foot syndrome was especially high in a study in which sorafenib was combined with 5-FU (55 %) [34] and in another in which sorafenib was combined with oxaliplatin and the 5-FU pro-drug capecitabine (73 %) [35] . In one study in which sorafenib was combined with tegafur (another 5-FU pro-drug), however, the frequency of hand-foot syndrome was only 9 % [37] . Among five studies on sorafenib combined with other treatment that provided data on OS, four (80 %) reported an OS that was [10 months. Among five studies on sorafenib combined with other treatment that provided data on TTP, four (80 %) reported a TTP [6 months. Among 11 studies on sorafenib combined with other treatment that provided data on DCR, 8 (73 %) described a DCR [60 %.
In summary, studies of sorafenib combined with other treatment have patient populations similar to those of studies of sorafenib alone (i.e. they comprised primarily men under age 70 who had advanced HCC with Child A cirrhosis). The number of patients included in each study generally is much smaller than that of the studies of sorafenib alone. Overall, reports on sorafenib combined with other treatment report better OS, TTP, and DCR than those reported for trials of sorafenib alone, but the studies are not directly comparable. Combination of sorafenib with other agents does not seem to result in inordinate toxicity, but hand-foot syndrome seems to be especially frequent when sorafenib is combined with 5-FU or some of its derivatives.
Discussion
This systematic review shows that sorafenib treatment results in statistically significant, but clinically modest, improvements in OS, TTP, and DCR for patient populations comprising predominantly men under age 70 with advanced HCC and Child A cirrhosis. In two randomized, placebo-controlled trials, sorafenib treatment prolonged OS by 2.3 to 2.8 months (from 4.2 to 6.5 months in one study [27] , and from 7.9 to 10.7 months in the other [26] ), extended the TTP by 1.4 to 2.7 months (from 1.4 to 2.8 months in one study [27] , and from 2.8 to 5.5 months in the other [26] ), and increased the DCR by 11-19 % (from 16 to 35 % in one study [27] , and from 32 to 43 % in the other [26] ). Uncontrolled studies of sorafenib alone have described OS as long as 15.6 months and DCR as high as 82 % but, with no control group, the contribution of sorafenib to these outcomes is not clear.
The most frequently described side effects of sorafenib are diarrhea, fatigue, and hand-foot syndrome (palmoplantar erythrodysesthesia), a troublesome condition characterized by painful, erythematous, blistering patches and plaques that involve the palms and soles of the feet primarily. Hand-foot syndrome has been associated with some antineoplastic agents, especially 5-fluoruracil (5-FU) and its derivatives, and the pathogenesis is not understood [46] . In most of the reports included in this systematic review, major side effects of sorafenib were reported for fewer than 15 % of patients. However, the frequency of adverse events widely varied among the studies, with some reports describing major side effects in more than 90 % of cases. Our review suggests that advanced cirrhosis might predispose patients undergoing sorafenib treatment to development of hand-foot syndrome. The study of treatment with sorafenib alone of patients with the highest percentage of Child B cirrhosis (52 %) also reported the highest the incidence of hand-foot syndrome (27 %) [31] . However, most studies included too few patients with advanced cirrhosis (i.e. Child B and C) to establish this association. Our review also suggests that hand-foot syndrome might be especially likely when sorafenib is combined with 5-FU or some of its derivatives. The frequency of hand-foot syndrome was 55 % in a study in which sorafenib was combined with 5-FU [34] , and 73 % in a study in which sorafenib was combined with oxaliplatin and capecitabine, a pro-drug that is enzymatically converted to 5-FU [35] . However, the frequency of hand-foot syndrome was not inordinately high (9 %) in one study in which sorafenib was combined with tegafur, another 5-FU prodrug [37] . It is not possible to establish meaningful conclusions on the safety and efficacy of sorafenib for treatment of HCC in women, the elderly, and patients with advanced cirrhosis (Child B and C). The large majority of patients included in the reports identified by our systematic review were men under the age of 70 who had HCC associated with Child A cirrhosis. Our systematic review does suggest that patients with hepatitis B infection might have a poorer response to sorafenib treatment than patients with hepatitis C. The trial with the highest percentage of hepatitis B patients (90 %) reported the lowest OS (5 months) and DCR (26 %) [30] , whereas the trial with the highest percentage of hepatitis C patients (74 %) reported the longest OS (15.6 months) and the highest DCR (82 %) [31] . Further studies that directly compare the response to sorafenib of patients who have HCC associated with hepatitis B and C are needed to establish this relationship.
Prospective studies on the treatment of HCC have evaluated the safety and efficacy of sorafenib combined with several systemic chemotherapeutic agents, including the anthracycline antibiotic doxorubicin, pyrimidine analogues (5-FU, capecitabine, tegafur/uracil, gemcitabine), DNA crosslinking agents (mitomycin c, cisplatin, oxaliplatin), octreotide, and AVE1642 (a humanized monoclonal antibody that binds the insulin-like growth factor 1 receptor). In addition, prospective studies have evaluated sorafenib combined with TACE, in which a chemotherapeutic agent mixed with embolic material is administered through a catheter positioned in branches of the hepatic artery that supply the HCC. TACE creates a hypoxic environment for the residual tumor cells [47] . This hypoxia stimulates surviving cells to express VEGF, which can lead to neovascularization and reestablishment of the tumor's blood supply [48] [49] [50] [51] . Thus, an anti-angiogenesis agent, for example sorafenib, which can inhibit VEGF receptors seems a good choice for combination with TACE.
In general, the reports on sorafenib combined with other treatment summarized in Table 2 describe better OS, TTP, and DCR than those described in reports on sorafenib alone. However, all but one of the studies on sorafenib combined with other treatment are relatively small and uncontrolled case series, and it is not appropriate to compare the results of these studies directly with those from studies of sorafenib alone. The only published randomized, controlled trial of combined treatment found that patients who received doxorubicin and sorafenib had significantly better OS (13.7 vs. 6.5 months), TTP (6.4 vs. 2.8 months), and DCR (62 vs. 29 %) than those treated with doxorubicin and placebo. This shows that sorafenib plus doxorubicin is better than doxorubicin alone, but does not establish that combination therapy is better than sorafenib alone. Well designed, placebo-controlled studies on this are sorely needed.
